Literature DB >> 33325636

Down-regulation of EOMES drives T-cell exhaustion via abolishing EOMES-mediated repression of inhibitory receptors of T cells in liver cancer.

Hongwei He1,2, Yong Yi2, Xiaoyan Cai3, Jiaxing Wang4, Xiaochun Ni5, Yipeng Fu6, Shuangjian Qiu2.   

Abstract

T-cell exhaustion is one of the hallmarks in cancer, but the mechanisms underlying T-cell dysregulation remains unclear. Here, we reported that down-regulation of transcription factor EOMES contributed to increased levels of inhibitory receptors in T cell among the tumour tissues and resulted in the poor prognosis of hepatocellular carcinoma (HCC). By analysing the correlation between EOMES in tumour-infiltrating T cells and the clinical features, we demonstrated that the EOMES was related to the advanced stage and poor prognosis of HCC. Further mechanistic studies revealed that the EOMES mainly expressed in the CD8+ T cells and were down-regulated in tumour samples. Moreover, we demonstrated that the EOMES directly bound at the transcriptional regulatory regions of the key inhibitory factors including PD-1, CTAL-4 and CD39, and lower levels of EOMES contributed to overexpression of these factors in T cells. Together, our studies provide new insight into the transcriptional deregulation of the inhibitory receptors on T cells during the tumorigenesis.
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Entities:  

Keywords:  PD-1/CTAL-4; T cells; eomesodermin; hepatocellular carcinoma; inhibitory receptors

Year:  2020        PMID: 33325636      PMCID: PMC7810931          DOI: 10.1111/jcmm.15898

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.310


  42 in total

1.  Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin.

Authors:  Andrew M Intlekofer; Naofumi Takemoto; E John Wherry; Sarah A Longworth; John T Northrup; Vikram R Palanivel; Alan C Mullen; Christopher R Gasink; Susan M Kaech; Joseph D Miller; Laurent Gapin; Kenneth Ryan; Andreas P Russ; Tullia Lindsten; Jordan S Orange; Ananda W Goldrath; Rafi Ahmed; Steven L Reiner
Journal:  Nat Immunol       Date:  2005-11-06       Impact factor: 25.606

2.  T-bet and eomesodermin play critical roles in directing T cell differentiation to Th1 versus Th17.

Authors:  Yu Yang; Jiangnan Xu; Yanyan Niu; Jonathan S Bromberg; Yaozhong Ding
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

3.  Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer.

Authors:  Alessia Errico
Journal:  Nat Rev Clin Oncol       Date:  2014-12-23       Impact factor: 66.675

Review 4.  Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.

Authors:  John D Martin; Horacio Cabral; Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2020-02-07       Impact factor: 66.675

5.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

6.  PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.

Authors:  Benjamin A Kansy; Fernando Concha-Benavente; Raghvendra M Srivastava; Hyun-Bae Jie; Gulidanna Shayan; Yu Lei; Jessica Moskovitz; Jennifer Moy; Jing Li; Sven Brandau; Stephan Lang; Nicole C Schmitt; Gordon J Freeman; William E Gooding; David A Clump; Robert L Ferris
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701

7.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

8.  Control of effector CD8+ T cell function by the transcription factor Eomesodermin.

Authors:  Erika L Pearce; Alan C Mullen; Gislâine A Martins; Connie M Krawczyk; Anne S Hutchins; Valerie P Zediak; Monica Banica; Catherine B DiCioccio; Darrick A Gross; Chai-An Mao; Hao Shen; Nezih Cereb; Soo Y Yang; Tullia Lindsten; Janet Rossant; Christopher A Hunter; Steven L Reiner
Journal:  Science       Date:  2003-11-07       Impact factor: 47.728

9.  Transcriptional insights into the CD8(+) T cell response to infection and memory T cell formation.

Authors:  J Adam Best; David A Blair; Jamie Knell; Edward Yang; Viveka Mayya; Andrew Doedens; Michael L Dustin; Ananda W Goldrath
Journal:  Nat Immunol       Date:  2013-02-10       Impact factor: 25.606

10.  Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas.

Authors:  Caroline Kampf; Ingmarie Olsson; Urban Ryberg; Evelina Sjöstedt; Fredrik Pontén
Journal:  J Vis Exp       Date:  2012-05-31       Impact factor: 1.355

View more
  2 in total

1.  Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape.

Authors:  Lingli Huang; Xin Liu; Li Li; Lei Wang; Nan Wu; Zhixian Liu
Journal:  Med Oncol       Date:  2022-05-15       Impact factor: 3.064

2.  Down-regulation of EOMES drives T-cell exhaustion via abolishing EOMES-mediated repression of inhibitory receptors of T cells in liver cancer.

Authors:  Hongwei He; Yong Yi; Xiaoyan Cai; Jiaxing Wang; Xiaochun Ni; Yipeng Fu; Shuangjian Qiu
Journal:  J Cell Mol Med       Date:  2020-12-16       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.